NewAmsterdam Pharma Co N.V. 4

Chief Accounting Officer Louise Frederika Kooij exercised 105,000 stock options and sold 104,? shares of NewAmsterdam Pharma Co N.V. ordinary shares on July 20, 2026, retaining 24,353 shares afterward.

On July 20, 2026, NewAmsterdam Pharma Co N.V. Chief Accounting Officer Louise Frederika Kooij exercised two tranches of stock options and sold a substantial portion of the resulting shares under a Rule 10b5-1 plan. She exercised 25,000 options at $11.90 and 80,000 options at $11.17 per share, acquiring 105,000 ordinary shares at those strike prices. On the same day, she sold 70,200 shares at a weighted average price of $29.96, 31,885 shares at $31.05, and 2,915 shares at $31.71, all through multiple trades within narrow price ranges as disclosed in the footnotes. The option exercises represent non-cash, compensatory transactions, while the follow-on sales appear to be at least partly for liquidity or tax/cash realization, but were pre-arranged under a 10b5-1 plan adopted in February 2026. After these transactions, Kooij retained 24,353 ordinary shares, including 22,000 shares underlying unvested RSU awards, implying a modest residual direct equity stake following the net exercise-and-sell activity.

Filing Facts

CIK

1936258

Ticker

NAMS

Form

4

Source Type

fda

Accession

0001193125-26-312387

Alert Tier

6